Daily Medication Pearl: Diroximel Fumarate (Vumerity)

Diroximel fumarate (Vumerity) is indicated for the treatment of relapsing forms of multiple sclerosis.

Medication Pearl of the Day: Diroximel fumarate (Vumerity)

Indication: Diroximel fumarate (Vumerity)is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Insight:

  • Dosing: Starting dose 231 mg twice a day, orally, for 7 days. Maintenance dose after 7 days 462 mg administered as two 231 mg capsules twice a day, orally.
  • Dosage forms: Delayed-release capsules 231 mg.
  • Adverse events: Most common adverse reactions for dimethyl fumarate were flushing, abdominal pain, diarrhea, and nausea.
  • Mechanism of action: MMF, the active metabolite of diroximel fumarate, has been shown to activate the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathways in vitro and in vivo in animals and humans. The Nrf2 pathway is involved in the cellular response to oxidative stress. MMF has been identified as a nicotinic acid receptor agonist in vitro.
  • Manufacturer: Biogen

Sources:

vumerity-prescribing-information.pdf

vumerity image - Google Search